Overview

Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

Status:
Terminated
Trial end date:
2010-06-24
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to treat laboratory confirmed cutaneous leishmaniasis with WR 279,396 in military health care beneficiaries. In this study "cutaneous leishmaniasis" is defined as Old World Leishmaniasis if acquired in the Southwest Central Asia/Middle East.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command
Collaborator:
Walter Reed Army Medical Center
Treatments:
Gentamicins
Paromomycin